Companies Dominating the Urothelial Carcinoma Treatment Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc
- Novartis AG
- Dendreon Pharmaceuticals LLC
- Sanofi SA
- F. Hoffmann-La-Roche AG
- UroGen Pharma Ltd
- Koninklijke Philips N.V.
- Olympus Corporation
- AstraZeneca PLC
Browse Key Market Insights with Data Illustration:
In the News
-
Olympus Corporation announced a binding agreement to purchase London-based cloud-AI endoscopy business Odin Vision, which offers a wide range of commercially available computer-aided detection/diagnostic (CAD) solutions. With the agreement, Olympus is able to provide cutting-edge AI-powered solutions and data-driven insights that improve clinical and procedural procedures and change patient care.
-
Sanofi SA licensed an NK cell engager program from Innate's ANKETTM (Antibody-based NK Cell Engager Therapies) technology that targets B7H3. This extended partnership with Innate Pharma will enable Sanofi to have the option of including up to two more ANKETTM targets, and be in control of all development, manufacture, and marketing.
